...
首页> 外文期刊>DNA and Cell Biology >Gene Therapy of Rat Malignant Gliomas Using Neural Stem Cells Expressing IL-12
【24h】

Gene Therapy of Rat Malignant Gliomas Using Neural Stem Cells Expressing IL-12

机译:表达IL-12的神经干细胞对大鼠恶性胶质瘤的基因治疗

获取原文
获取原文并翻译 | 示例
           

摘要

Primary malignant brain tumors have a poor prognosis. This report investigates the potential for gene therapy of experimental brain tumors using neural stem cells (NSCs) expressing IL-12. In this study NSCs were isolated from the hippocampi of 3-5-month human embryos and used for lipofectamine mediated transfer of the IL-12 gene. Positive clones of anti-G418 were obtained and were proliferated in culture and expression of IL-12 was demonstrated by RT-PCR. For the in vivo studies three groups of rats were used and stereotactic injections were made into the striatum. In the first group C6 tumor cells were injected, in the second C6 cells and hNSCs. IL-12, and in the third C6 cells on Day 0 followed by hNSCs.IL-12 on day 5. The growth of the resulting tumors was monitored by magnetic resonance imaging (MRI) and after sacrifice by immunohistochemistry. Rats injected with C6 cells and hNSCs.IL-12 had a significantly prolonged survival. Injections of hNSCs.IL-12 were also made into established gliomas. The survival time was also significantly prolonged compared to controls. MR imaging demonstrated that there was initial growth of tumor followed by shrinkage and then disappearance. After sacrifice, tumor areas were studied by histochemistry. NSCs were often seen intermingled with tumor cells, particularly when they had been injected into established tumors; they were also present at the boundaries of the tumor mass. The immunohistochemical analysis showed that these infiltrates were mostly constituted by CD4+ and CD8+ T-lymphocytes, the CD8+ being more numerous than the CD4+. These findings indicated that NSCs engineered to release IL-12 could have a strong antitumor effect. Neural stem/precursor cells could be useful vectors in genetic approaches to brain tumors
机译:原发性恶性脑肿瘤预后不良。本报告调查了使用表达IL-12的神经干细胞(NSC)对实验性脑肿瘤进行基因治疗的潜力。在这项研究中,从3到5个月人类胚胎的海马中分离出NSC,并将其用于lipofectamine介导的IL-12基因的转移。获得了抗G418的阳性克隆,并在培养物中增殖,并且通过RT-PCR证实了IL-12的表达。为了进行体内研究,使用三组大鼠并将立体定向注射到纹状体中。在第一组中,注射了C6肿瘤细胞,在第二组中,注射了hNSCs。 IL-12,第0天是第三个C6细胞,第5天是hNSCs.IL-12。通过磁共振成像(MRI)监测所得肿瘤的生长,并通过免疫组织化学处死。注射C6细胞和hNSCs.IL-12的大鼠存活时间明显延长。还将hNSCs.IL-12注射入已建立的神经胶质瘤中。与对照组相比,存活时间也显着延长。 MR成像显示,肿瘤最初生长,然后缩小,然后消失。处死后,通过组织化学研究肿瘤区域。神经干细胞通常与肿瘤细胞混合在一起,尤其是在将其注射入已建立的肿瘤中时;它们也存在于肿瘤块的边界。免疫组织化学分析显示,这些浸润液主要由CD4 +和CD8 + T淋巴细胞组成,其中CD8 +比CD4 +多。这些发现表明,被设计释放IL-12的NSC可能具有很强的抗肿瘤作用。神经干/前体细胞可能是脑肿瘤遗传学方法中的有用载体

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号